Alpha Cognition Inc. (ACOG): EBITDA
-$22.60M
Year ended 2025-12-31
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$22.60M | n/m | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | -$11.93M | n/c | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | -$9.85M | n/a | 2025-03-31, From 2023-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | -$22.60M | n/m |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | -$132.91M | n/m |
| Curis Inc (CRIS) | 2025-12-31 | -$5.54M | n/m |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | -$144.70M | n/m |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$35.92M | n/m |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | -$134.80M | n/m |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | -$144.07M | n/m |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | -$90.85M | n/m |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | -$5.31M | n/m |
Compare ACOG, TCRX, CRIS, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗